Blueprint Medicines Profit Margin

The latest profit margin for BPMC is -27.7% as of March 2025. That compares with -102.15% in the prior-year period — up 72.9% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Blueprint Medicines's historical trend and sector peers before judging valuation or financial health.

Over the past year, BPMC's profit margin moved from -102.15% to -27.7% — a 72.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Blueprint Medicines's valuation or profitability profile.

Against Healthcare companies, BPMC currently prints -27.7% for profit margin, while the sector average sits near 21.34%. That is roughly 229.9% below the sector mean. Large gaps often invite a closer look at Blueprint Medicines's growth, margins, and balance sheet.

Profit Margin shows how effectively Blueprint Medicines converts resources into returns. At -27.7%, BPMC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -102.15% in the prior-year period — up 72.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BPMC's profit margin (-27.7%), review year-over-year change from -102.15%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.